Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer

Apolipoprotein D (ApoD) is a small glycoprotein of 24 kD, and a member of the lipocalin family. ApoD exerts several intracellular mechanistic roles, especially ligand binding. Some putative ligands are arachidonic acid, progesterone, and tamoxifen. It probably has a binding/reservoir function of the...

Full description

Saved in:
Bibliographic Details
Main Authors: Håvard Søiland, Kjetil Søreide, Emiel A. M. Janssen, Hartwig Körner, Jan P.A. Baak, Jon Arne Søreide
Format: Article
Language:English
Published: Wiley 2007-01-01
Series:Cellular Oncology
Online Access:http://dx.doi.org/10.1155/2007/487235
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849472824620613632
author Håvard Søiland
Kjetil Søreide
Emiel A. M. Janssen
Hartwig Körner
Jan P.A. Baak
Jon Arne Søreide
author_facet Håvard Søiland
Kjetil Søreide
Emiel A. M. Janssen
Hartwig Körner
Jan P.A. Baak
Jon Arne Søreide
author_sort Håvard Søiland
collection DOAJ
description Apolipoprotein D (ApoD) is a small glycoprotein of 24 kD, and a member of the lipocalin family. ApoD exerts several intracellular mechanistic roles, especially ligand binding. Some putative ligands are arachidonic acid, progesterone, and tamoxifen. It probably has a binding/reservoir function of these ligands in the cytoplasm. Furthermore, ApoD has features compatible with endosomal trafficking, proteolytic activity and interactions in cellular signal pathways. ApoD inhibits translocation of phosphorylated MAPK into the nucleus. Moreover, ApoD is associated with reduced proliferative activity of cancer cells, and is abundantly raised in senescent cells. In breast cancer, ApoD expression is associated with favourable histology and clinical stage, whereas in adjacent tumour stroma ApoD expression is a marker of adverse prognosis. Oestrogen receptor expression in breast cancer is inversely related to ApoD expression. Therefore, a combined oestrogen receptor positivity/ApoD positivity, could reflect a non-functional oestrogen receptor pathway, and this subset of breast cancer patients does not react to adjuvant tamoxifen treatment. The triangular relationship between oestrogen receptor, tamoxifen and ApoD should be further explored.
format Article
id doaj-art-d9dff6ccd5714a96af3388dbeb4c5ec5
institution Kabale University
issn 1570-5870
1875-8606
language English
publishDate 2007-01-01
publisher Wiley
record_format Article
series Cellular Oncology
spelling doaj-art-d9dff6ccd5714a96af3388dbeb4c5ec52025-08-20T03:24:24ZengWileyCellular Oncology1570-58701875-86062007-01-0129319520910.1155/2007/487235Emerging Concepts of Apolipoprotein D with Possible Implications for Breast CancerHåvard Søiland0Kjetil Søreide1Emiel A. M. Janssen2Hartwig Körner3Jan P.A. Baak4Jon Arne Søreide5Department of Surgery, Stavanger University Hospital, Stavanger, University of Bergen, NorwayDepartment of Pathology, Stavanger University Hospital, Stavanger, University of Bergen, NorwayDepartment of Pathology, Stavanger University Hospital, Stavanger, University of Bergen, NorwayDepartment of Surgery, Stavanger University Hospital, Stavanger, University of Bergen, NorwayDepartment of Pathology, Stavanger University Hospital, Stavanger, University of Bergen, NorwayDepartment of Surgery, Stavanger University Hospital, Stavanger, University of Bergen, NorwayApolipoprotein D (ApoD) is a small glycoprotein of 24 kD, and a member of the lipocalin family. ApoD exerts several intracellular mechanistic roles, especially ligand binding. Some putative ligands are arachidonic acid, progesterone, and tamoxifen. It probably has a binding/reservoir function of these ligands in the cytoplasm. Furthermore, ApoD has features compatible with endosomal trafficking, proteolytic activity and interactions in cellular signal pathways. ApoD inhibits translocation of phosphorylated MAPK into the nucleus. Moreover, ApoD is associated with reduced proliferative activity of cancer cells, and is abundantly raised in senescent cells. In breast cancer, ApoD expression is associated with favourable histology and clinical stage, whereas in adjacent tumour stroma ApoD expression is a marker of adverse prognosis. Oestrogen receptor expression in breast cancer is inversely related to ApoD expression. Therefore, a combined oestrogen receptor positivity/ApoD positivity, could reflect a non-functional oestrogen receptor pathway, and this subset of breast cancer patients does not react to adjuvant tamoxifen treatment. The triangular relationship between oestrogen receptor, tamoxifen and ApoD should be further explored.http://dx.doi.org/10.1155/2007/487235
spellingShingle Håvard Søiland
Kjetil Søreide
Emiel A. M. Janssen
Hartwig Körner
Jan P.A. Baak
Jon Arne Søreide
Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
Cellular Oncology
title Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
title_full Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
title_fullStr Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
title_full_unstemmed Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
title_short Emerging Concepts of Apolipoprotein D with Possible Implications for Breast Cancer
title_sort emerging concepts of apolipoprotein d with possible implications for breast cancer
url http://dx.doi.org/10.1155/2007/487235
work_keys_str_mv AT havardsøiland emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer
AT kjetilsøreide emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer
AT emielamjanssen emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer
AT hartwigkorner emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer
AT janpabaak emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer
AT jonarnesøreide emergingconceptsofapolipoproteindwithpossibleimplicationsforbreastcancer